CREXONT now available in U.S. pharmacies nationwide
Comprehensive access and affordability services to be made available to Parkinson's patients and healthcare providers
Amneal to hold CREXONT launch symposium and scientific presentations at the International Congress of Parkinson's Disease and Movement Disorders on Sept. 27 – Oct. 1, 2024
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company") today announced that it has launched CREXONT (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson's disease. CREXONT is a novel, oral formulation of carbidopa/levodopa (CD/LD) that combines both immediate-release granules and extended-release pellets. CREXONT is now broadly available at U.S. pharmacies.
